jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-5-69-77jofin-1428Research ArticleФармакоэкономикаPharmacoeconomicsЭффективность затрат на вакцинацию пятивалентной вакциной против ротавирусной инфекции в Российской ФедерацииСost-effectiveness of pentavalent rotavirus vaccination in the Russian FederationРудаковаА. В.RudakovaA. V.

Алла Всеволодовна Рудакова, старший научный сотрудник, д. фарм.н., профессор

отдел организации медицинской помощи

Санкт-Петербург

тел.: +7-921-908-73-49

Saint-Petersburg

rudakova_a@mail.ruХаритС. М.KharitS. M.

Сусанна Михайловна Харит, руководитель отдела, д. м. н., профессор

отдел профилактики инфекционных заболеваний

Санкт-Петербург

тел. +7-905-213-53-23

Saint-Petersburg

kharit-s@mail.ruРычковаС. В.RychkovaS. V.

Светлана Владиславовна Рычкова, руководитель отдела, д. м. н., доцент

отдел организации медицинской помощи

Санкт-Петербург

тел.: +7-921-310-65-81

Saint-Petersburg

rychkova.sv@niidi.ruЛобзинЮ. В.LobzinYu. V.

Юрий Владимирович Лобзин, президент центра, д. м. н., профессор, академик РАН, главный внештатный специалист по инфекционным болезням у детей МЗ РФ

Санкт-Петербург

Saint-Petersburg

niidi@niidi.ruДетский научно-клинический центр инфекционных болезнейРоссияPediatric Research and Clinical Center for Infectious DiseasesRussian FederationДетский научно-клинический центр инфекционных болезней; РАН ; МЗ РФРоссияPediatric Research and Clinical Center for Infectious DiseasesRussian Federation2022010120231456977Copyright © Рудакова А.В., Харит С.М., Рычкова С.В., Лобзин Ю.В., 20232023Рудакова А.В., Харит С.М., Рычкова С.В., Лобзин Ю.В.Rudakova A.V., Kharit S.M., Rychkova S.V., Lobzin Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1428

   Одна из основных причин заболеваемости кишечными инфекциями у детей до 5 лет – инфицирование ротавирусами. Вакцины против ротавирусной инфекции существенно снижают заболеваемость.   Цель: оценка эффективности затрат на массовую вакцинацию детей 5-валентной вакциной против ротавирусной инфекции в Российской Федерации.   Материалы и методы. Оценка осуществлялась с помощью моделирования на основе опубликованных данных по эффективности вакцины и эпидемиологических показателей по Российской Федерации. Анализ проводили с позиции общества в целом и системы здравоохранения с горизонтом 5 лет. Затраты на терапию ротавирусной инфекции соответствовали тарифам обязательного медицинского страхования по Санкт-Петербургу на 2022 г., цена 1 дозы вакцины – зарегистрированной цене с учетом налога на добавочную стоимость. Затраты и продолжительность жизни с учетом качества дисконтировали на 3,5 % в год.   Результаты. С учетом принятых допущений, массовая вакцинация позволит предупредить в среднем 468 637 случаев ротавирусной инфекции за 5 лет. Предотвращенные прямые медицинские затраты, т. е. затраты на лечение ротавирусной инфекции, составят 53,4 %, а недополученный вследствие временной нетрудоспособности доход – 46,6 % от общего объема предотвращенных затрат. При этом объем предотвращенных затрат на 61,4 % обусловлен снижением заболеваемости в вакцинированной популяции, а на 38,6 % – развитием популяционного эффекта при массовой вакцинации. Прогнозируемая величина общего объема предотвращенных затрат на 1 вакцинируемого – 2,975 тыс. руб. Эффективность затрат на вакцину «Рота-V-Эйд» составит при оценке с позиции общества в целом 364,813 тыс. руб. в расчете на дополнительный год жизни с учетом качества (QALY), а при оценке с позиции системы здравоохранения – 1726,399 тыс. руб. / QALY. Таким образом, в обоих случаях коэффициент эффективности дополнительных затрат на вакцинацию против ротавирусной инфекции не превысит общепринятого порога готовности платить, равного утроенной величине валового внутреннего продукта на душу населения в РФ (по данным за 2021 г. – ~2,7 млн руб.). Прогнозируемая экономическая эффективность выборочной вакцинации существенно ниже, чем массовой вакцинации.   Выводы. Массовая вакцинация детей 5-валентной вакциной против ротавирусной инфекции позволит не только снизить заболеваемость в РФ, но, с учетом принятых допущений, может также рассматриваться как экономически эффективное вмешательство.

   One of the main causes of acute gastroenteritis in children under 5 years of age is rotavirus infection (RVI). Vaccines against RVI significantly reduce the incidence.   Aim. To evaluate the cost-effectiveness of mass vaccination of children with a 5-valent RVI vaccine in the Russian Federation.   Materials and methods. The assessment was carried out using modeling based on published data on the effectiveness of the vaccine and epidemiological indicators in the Russian Federation. The analysis was carried out from the perspective of the health care system and society as a whole with a 5-year horizon. The cost of RVI therapy corresponded to the compulsory health insurance tariffs for St. Petersburg for 2022, the price of 1 dose of the vaccine was the registered price, including VAT. Costs and life expectancy, taking into account quality, were discounted at 3.5 % per year.   Results. Given the assumptions made, routine vaccination will prevent an average of 468,637 cases of RVI over 5 years. Avoided direct medical costs, i. e. RVI treatment costs will amount to 53,4 %, and lost income due to temporary disability – 46,6 % of the total avoided costs. At the same time, the volume of avoided costs is 61,4 % due to a decrease in morbidity in the vaccinated population, and 38.6 % due to the development of a indirect effect. The predicted avoided costs per 1 vaccinated person is 2,975 thousand rubles. From a societal perspective, the cost-effectiveness of the Rota-V-Aid vaccine will be 364,813 thousand rubles / QALY (quality-adjusted life year), and from a healthcare perspective – 1726,399 thousand rubles / QALY. Thus, in both cases, the cost-effectiveness of RVI vaccination will not exceed the generally accepted threshold of willingness to pay, equal to three times the gross domestic product per capita in the Russian Federation (according to data for 2021 – ~2,7 million rubles). The predicted cost-effectiveness of selective vaccination is significantly lower than that of mass vaccination.   Conclusions. Mass vaccination of children with a 5-valent vaccine against RVI will not only reduce the incidence in the Russian Federation, but, taking into account the assumptions made, can also be considered as a cost-effective intervention.

ротавирусная инфекциявакцинацияэффективность затратrotavirus infectionvaccinationcost-effectivenessReferencesВасильев, Б. Я. Острые кишечные заболевания. Ротавирусы и ротавирусная инфекция / Б. Я. Васильев, Р. И. Васильева, Ю. В. Лобзин. – СПб., 2000.Vasil’ev B. Ya., Vasil’eva R. I., Lobzin Yu. V. Ostrye kishechnye zabolevaniya. Rotavirusy i rotavirusnaya infekciya. — SPb., 2000.World Health Organisation, Rotavirus vaccines. WHO Position Paper–January 2013. Wkly Epidemiol Rec 2013; 88 (5): 49–64.World Health Organisation, Rotavirus vaccines. WHO Position Paper–January 2013. Wkly Epidemiol Rec 2013; 88 (5): 49–64.Podkolzin A. T., Fenske E. B., Abramycheva N. Y. et al. Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007 // J Infect Dis. 2009 Nov 1; 200 Suppl 1:S228-33. doi: 10.1086/605054.Podkolzin A. T., Fenske E. B., Abramycheva N. Y. et al. Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007 // J Infect Dis. 2009 Nov 1; 200 Suppl 1:S228-33. doi: 10.1086/605054.Подколзин, А. Т. Эпидемиологическая и клиническая характеристика острых кишечных инфекций вирусной этиологии в Российской Федеерации : автореф. дис. … д. м. н. / А. Т. Подклзин. – М.: ФГБУ «ЦНИИ эпидемиологии» Роспотребнадзора. – 46 с.Podkolzin A. T. Epidemiologicheskaya i klinicheskaya harakteristika ostryh kishechnyh infekcij virusnoj etiologii v Rossijskoj Fedeeracii. - Avtoref. dis. … d. m. n..- Moskva. - FGBU «CNII epidemiologii» Rospotrebnadzora. - 46 s.О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2021 году: Государственный доклад. – М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2022. – 340 с.O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2021 godu: Gosudarstvennyj doklad. M.: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka, 2022. 340 s.Каждаева, Э. П. Этиологическая структура и вопросы этиотропной терапии острых кишечных инфекций бактериальной этиологии у детей : автореф. канд. дисс. … к. м. н. / Э. П. Каждаева. – М.: Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора, 2006. – 23 с.Kazhdaeva E. P. Etiologicheskaya struktura i voprosy etiotropnoj terapii ostryh kishechnyh infekcij bakterial’noj etiologii u detej. - Avtoref. kand. diss. … k. m. n.- Central’nyj nauchno-issledovatel’skij institut epidemiologii Rospotrebnadzora. - 2006. - 23 s.Karafillakis E., Hassounah S., Atchison C. Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014 // Vaccine 33 (2015) 2097–2107.Karafillakis E., Hassounah S., Atchison C. Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014 // Vaccine 33 (2015) 2097–2107.Paulke-Korinek M., Kollaritsch H., Aberle S. W., et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria // Vaccine 2013; 31 (24): 2686–91.Paulke-Korinek M., Kollaritsch H., Aberle S. W., et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria // Vaccine 2013; 31 (24): 2686–91.Braeckman T., Van Herck K., Meyer N., et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study // BMJ 2012;345: e4752.Braeckman T., Van Herck K., Meyer N., et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study // BMJ 2012;345: e4752.Vesikari T., Uhari M., Renko M., et al. Impact and effectiveness of RotaTeq vac-cine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland // Pediatr Infect Dis J 2013; 32 (12): 1365–73.Vesikari T., Uhari M., Renko M., et al. Impact and effectiveness of RotaTeq vac-cine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland // Pediatr Infect Dis J 2013; 32 (12): 1365–73.Adlhoch C., Hoehne M., Littmann M., et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany:2010–2011 // Pediatr Infect Dis J 2013; 32 (2): e82–9.[12]Adlhoch C., Hoehne M., Littmann M., et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany:2010–2011 // Pediatr Infect Dis J 2013; 32 (2): e82–9.[12]Muhsen K., Shulman L., Kasem E., et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study // Hum Vaccin 2010; 6 (6): 450–4.Muhsen K., Shulman L., Kasem E., et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study // Hum Vaccin 2010; 6 (6): 450–4.Muhsen K., Chodick G., Goren S., Shalev V., Cohen D. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community // Vaccine 2010; 29 (1): 91–4Muhsen K., Chodick G., Goren S., Shalev V., Cohen D. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community // Vaccine 2010; 29 (1): 91–4Bellido-Blasco J. B., Sabater-Vidal S., Salvador-Ribera Md. M., et al. Rotavirus vaccination effectiveness: a case-case study in the EDICS project, Castellon (Spain) // Vaccine 2012; 30 (52): 7536–40.Bellido-Blasco J. B., Sabater-Vidal S., Salvador-Ribera Md. M., et al. Rotavirus vaccination effectiveness: a case-case study in the EDICS project, Castellon (Spain) // Vaccine 2012; 30 (52): 7536–40.Castilla J., Beristain X., Martinez-Artola V., et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre: Spain // Vaccine 2012; 30 (3): 539–43.Castilla J., Beristain X., Martinez-Artola V., et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre: Spain // Vaccine 2012; 30 (3): 539–43.Martinon-Torres F., Bouzon Alejandro M., Redondo Collazo L., et al. Effectiveness of rotavirus vaccination in Spain // Hum Vaccin 2011; 7 (7): 757–61.Martinon-Torres F., Bouzon Alejandro M., Redondo Collazo L., et al. Effectiveness of rotavirus vaccination in Spain // Hum Vaccin 2011; 7 (7): 757–61.Vesikari T., Itzler R., Karvonen A., et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe // Vaccine 2009; 28 (2): 345–51.Vesikari T., Itzler R., Karvonen A., et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe // Vaccine 2009; 28 (2): 345–51.Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T. First year experience of rotavirus immunisation programme in Finland // Vaccine 2012; 31 (1): 176–82.Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T. First year experience of rotavirus immunisation programme in Finland // Vaccine 2012; 31 (1): 176–82.Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria // Vaccine 2011; 29: 2791–6.Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria // Vaccine 2011; 29: 2791–6.Standaert B., Strens D., Alwan A., Raes M. Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the rotavirus Belgium impact study (RotaBIS) // Infect Dis Therapy 2016; 5: 31–44.Standaert B., Strens D., Alwan A., Raes M. Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the rotavirus Belgium impact study (RotaBIS) // Infect Dis Therapy 2016; 5: 31–44.Atchison C. J., Stowe J., Andrews N., Collins S., Allen D. J., Nawaz S., et al. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales // J Infect Dis 2016; 213: 243–9.Atchison C. J., Stowe J., Andrews N., Collins S., Allen D. J., Nawaz S., et al. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales // J Infect Dis 2016; 213: 243–9.Yen C., Armero Guardado J. A., Alberto P., Rodriguez Araujo D. S., Mena C., Cuellar E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador // Ped Infect Dis J 2011; 30: S6–S10.Yen C., Armero Guardado J. A., Alberto P., Rodriguez Araujo D. S., Mena C., Cuellar E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador // Ped Infect Dis J 2011; 30: S6–S10.Field E. J., Vally H., Grimwood K., Lambert S. B. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia // Pediatrics 2010; 126: e506–12.Field E. J., Vally H., Grimwood K., Lambert S. B. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia // Pediatrics 2010; 126: e506–12.Clarke M. F., Davidson G. P., Gold M. S., Marshall H. S. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination // Vaccine 2011; 29: 4663–7.Clarke M. F., Davidson G. P., Gold M. S., Marshall H. S. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination // Vaccine 2011; 29: 4663–7.Lopman B., Curns A., Yen C., Parashar U. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States // The Journal of Infectious Diseases 2011; 204: 980–6.Lopman B., Curns A., Yen C., Parashar U. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States // The Journal of Infectious Diseases 2011; 204: 980–6.Payne D. C., Staat M. A., Edwards K. M., Szilagyi P. G., Weinberg G. A., Hall C. B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006–2009 // Clin Infect Dis 2011; 53: 245–53.Payne D. C., Staat M. A., Edwards K. M., Szilagyi P. G., Weinberg G. A., Hall C. B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006–2009 // Clin Infect Dis 2011; 53: 245–53.Wilson S. E., Rosella L. C., Wang J., Le Saux N., Crowcroft N. S., Harris T., et al. (2016) Population-Level Impact of Ontario’s Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects // PLoS ONE 11 (5): e0154340. doi:10.1371/journal.pone.0154340Wilson S. E., Rosella L. C., Wang J., Le Saux N., Crowcroft N. S., Harris T., et al. (2016) Population-Level Impact of Ontario’s Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects // PLoS ONE 11 (5): e0154340. doi:10.1371/journal.pone.0154340Gagneur A., Nowak E., Lemaitre T., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study // Vaccine 2011; 29 (21): 3753–9, doi: 10.1016/j.vaccine.2011.03.035 (EpubApr 13).Gagneur A., Nowak E., Lemaitre T., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study // Vaccine 2011; 29 (21): 3753–9, doi: 10.1016/j.vaccine.2011.03.035 (EpubApr 13).Santos V. S., Marques D. P., Martins-Filho P. R., Cuevas L. E., Gurgel R. Q. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infect Dis Poverty. 2016 Aug 12; 5 (1): 83. doi: 10.1186/s40249-016-0173-2. PMID: 27514855; PMCID: PMC4982225.Santos V. S., Marques D. P., Martins-Filho P. R., Cuevas L. E., Gurgel R. Q. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infect Dis Poverty. 2016 Aug 12; 5 (1): 83. doi: 10.1186/s40249-016-0173-2. PMID: 27514855; PMCID: PMC4982225.Muhsen K., Anis E., Rubinstein U., Kassem E., Goren S., Shulman L. M., Ephros M., Cohen D. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. Clin Microbiol Infect. 2018 Jan; 24 (1): 53-59. doi: 10.1016/j.cmi.2017.04.018. Epub 2017 Apr 22. PMID: 28442435.Muhsen K., Anis E., Rubinstein U., Kassem E., Goren S., Shulman L. M., Ephros M., Cohen D. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study. Clin Microbiol Infect. 2018 Jan; 24 (1): 53-59. doi: 10.1016/j.cmi.2017.04.018. Epub 2017 Apr 22. PMID: 28442435.Bergman H., Henschke N., Hungerford D., Pitan F., Ndwandwe D., Cunliffe N., Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021 Nov 17; 11 (11): CD008521. doi: 10.1002/14651858.CD008521.pub6. PMID: 34788488; PMCID: PMC8597890.Bergman H., Henschke N., Hungerford D., Pitan F., Ndwandwe D., Cunliffe N., Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021 Nov 17; 11 (11): CD008521. doi: 10.1002/14651858.CD008521.pub6. PMID: 34788488; PMCID: PMC8597890.European Centre for Disease Prevention and Control. ECDC Expert opinion on rotavirus vaccination in infancy. Stockholm: ECDC; 2017.European Centre for Disease Prevention and Control. ECDC Expert opinion on rotavirus vaccination in infancy. Stockholm: ECDC; 2017.Shu-ling Hoshi, Masahide Kondo, Ichiro Okubo. Economic evaluation of routine infant rotavirus immunisation program in Japan // HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 5, 1115–1125. doi: 10.1080/21645515.2016.1245252Shu-ling Hoshi, Masahide Kondo, Ichiro Okubo. Economic evaluation of routine infant rotavirus immunisation program in Japan // HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL. 13, NO. 5, 1115–1125. doi: 10.1080/21645515.2016.1245252Aidelsburger P., Grabein K., Boehm K., Dietl M., Wasem J., Koch J., et al. Cost effectiveness of childhood rotavirus vaccination in Germany // Vaccine. 2014; 32: 1964–74.Aidelsburger P., Grabein K., Boehm K., Dietl M., Wasem J., Koch J., et al. Cost effectiveness of childhood rotavirus vaccination in Germany // Vaccine. 2014; 32: 1964–74.World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.Karmann A., Jurack A., Lukas D. Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data // Eur J Health Econ (2015) 16: 719–731.Karmann A., Jurack A., Lukas D. Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data // Eur J Health Econ (2015) 16: 719–731.Hansen Edwards C., de Blasio B. F., Salamanca B. V., Flem E. (2017) Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway // PLoS ONE 12 (8): e0183306. doi: 10.1371/journal.pone.0183306Hansen Edwards C., de Blasio B. F., Salamanca B. V., Flem E. (2017) Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway // PLoS ONE 12 (8): e0183306. doi: 10.1371/journal.pone.0183306Jit M., Mangen M. J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to the cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe // Vaccine 2010; 28 (47): 7457–9, doi: 10.1016/j.vaccine.2010.08.060 (EpubSep 21).Jit M., Mangen M. J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to the cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe // Vaccine 2010; 28 (47): 7457–9, doi: 10.1016/j.vaccine.2010.08.060 (EpubSep 21).Jit M., Edmunds W. J. Evaluating rotavirus vaccination in England and Wales. PartII. The potential cost-effectiveness of vaccination // Vaccine 2007; 25 (20): 3971–9 (Epub 2007 Mar 13).Jit M., Edmunds W. J. Evaluating rotavirus vaccination in England and Wales. PartII. The potential cost-effectiveness of vaccination // Vaccine 2007; 25 (20): 3971–9 (Epub 2007 Mar 13).Shuhui Cui, Ruoyan Gai Tobe, Xiuting Mo, Xiaoyan Liu, Lingzhong Xu, Shixue Li. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option // BMC Infectious Diseases (2016) 16: 677. DOI 10.1186/s12879-016-2013-1Shuhui Cui, Ruoyan Gai Tobe, Xiuting Mo, Xiaoyan Liu, Lingzhong Xu, Shixue Li. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option // BMC Infectious Diseases (2016) 16: 677. DOI 10.1186/s12879-016-2013-1Al Awaidy S., Gebremeskel B., Al Obeidani I., et al. Cost effectiveness of a pentavalent rotavirus vaccine in Oman // BMC Infectious Diseases 2014, 14: 334 http://www.biomedcentral.com/1471-2334/14/334Al Awaidy S., Gebremeskel B., Al Obeidani I., et al. Cost effectiveness of a pentavalent rotavirus vaccine in Oman // BMC Infectious Diseases 2014, 14: 334 http://www.biomedcentral.com/1471-2334/14/334Dan Yamin, Atkins K., Remy V., Galvani A. Cost-Effectiveness of Rotavirus Vaccination in France —Accounting for Indirect Protection // Value in Heath 2016; 19: 811 – 819.Dan Yamin, Atkins K., Remy V., Galvani A. Cost-Effectiveness of Rotavirus Vaccination in France —Accounting for Indirect Protection // Value in Heath 2016; 19: 811 – 819.Koksal T., et al., Cost-effectiveness of rotavirus vaccination in Turkey // Journal of Microbiology, Immunology and Infection (2016), doi: 10.1016/j.jmii.2016.03.005Koksal T., et al., Cost-effectiveness of rotavirus vaccination in Turkey // Journal of Microbiology, Immunology and Infection (2016), doi: 10.1016/j.jmii.2016.03.005Sun Z. W., Fu Y., Lu H. L., Yang R. X., Goyal H., Jiang Y., Xu H. G. Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies. JAMA Pediatr. 2021 Jul 1; 175 (7): e210347. doi: 10.1001/jamapediatrics.2021.0347. Epub 2021 Jul 6. PMID: 33970192; PMCID: PMC8111566.Sun Z. W., Fu Y., Lu H. L., Yang R. X., Goyal H., Jiang Y., Xu H. G. Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 Years: A Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies. JAMA Pediatr. 2021 Jul 1; 175 (7): e210347. doi: 10.1001/jamapediatrics.2021.0347. Epub 2021 Jul 6. PMID: 33970192; PMCID: PMC8111566.Rosettie K. L., Vos T., Mokdad A. H., Flaxman A. D., Khalil I., Troeger C., Weaver M. R. Indirect Rotavirus Vaccine Effectiveness for the Prevention of Rotavirus Hospitalization: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg. 2018 Apr; 98 (4): 1197-1201. doi: 10.4269/ajtmh.17-0705. Epub 2018 Feb 8. PMID: 29436336; PMCID: PMC5928826.Rosettie K. L., Vos T., Mokdad A. H., Flaxman A. D., Khalil I., Troeger C., Weaver M. R. Indirect Rotavirus Vaccine Effectiveness for the Prevention of Rotavirus Hospitalization: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg. 2018 Apr; 98 (4): 1197-1201. doi: 10.4269/ajtmh.17-0705. Epub 2018 Feb 8. PMID: 29436336; PMCID: PMC5928826.Мартынова, Г. П. Клинико-эпидемиологические особенности ротавирусной инфекции у детей первого года жизни / Г. П. Мартынова [и др.] // Журнал инфектологии. – 2014. – Т. 6, № 2. – С. 12–16. URL: https://journal.niidi.ru/jofin/article/view/231.Martynova G. P., Solov`eva I. A., Alexeenko A. N., Kuznetsova N. F., Yuzhakova A. G. Сlinical and epidemiological features of rotavirus infections in infants. Journal Infectology. 2014; 6 (2): 12-16. (In Russ.) URL: https://journal.niidi.ru/jofin/article/view/231.

The authors declare that there are no conflicts of interest present.